Item 173 | First Year - FY2021 | Second Year - FY2022 |
|---|---|---|
| Financial Assistance For Educational and General Services (11000) | $281,275,000 | $281,275,000 |
| Eminent Scholars (11001) | FY2021 $1,000,000 | FY2022 $1,000,000 |
| Sponsored Programs (11004) | FY2021 $280,275,000 | FY2022 $280,275,000 |
| Fund Sources: | ||
| General | FY2021 $2,106,250 | FY2022 $2,106,250 |
| Higher Education Operating | FY2021 $279,168,750 | FY2022 $279,168,750 |
Authority: Title 23.1, Chapter 15, Code of Virginia.
A. 1. Out of this appropriation, $956,250 the first year and $956,250 the second year from the general fund and $5,850,000 the first year and $5,850,000 the second year from nongeneral funds are designated to build research capacity in biomedical research and biomaterials engineering.
2. Out of this appropriation, $750,000 the first year and $750,000 the second year from the general fund is designated for applied research in simulation modeling and gaming.
B. Out of this appropriation, $125,000 the first year and $125,000 the second year from the general fund is designated for Lyme Disease research and medical test development.
C. The Higher Education Operating fund source listed in this Item is considered to be a sum sufficient appropriation, which is an estimate of funding required by the university to cover sponsored program operations.
D. Out of this appropriation, $275,000 the first year and $275,000 the second year from the general fund is designated for George Mason University, in collaboration with Eastern Virginia Medical School, Old Dominion University, the University of Virginia, Virginia Commonwealth University, Virginia Tech-Carilion, INOVA, and Sentara Health System, to create the Virginia Commonwealth Clinical Research Network to serve as a network of institutions to conduct significant clinical trials in areas that include oncology, mental health and substance abuse. The Virginia Commonwealth Clinical Research Network would facilitate identifying and recruiting patients and expand access for researchers to a clinical base thereby creating greater opportunities for grant funding and the development commercialization of breakthrough products and services.